Amgen Inc.
AMGN
Classificação em ações
#71
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Preço da ação
$436.87
Valor de mercado
$236.19B
Variação (1 dia)
2.81%
Variação (1 ano)
44.02%
País
US
Negociar Amgen Inc. (AMGN)
Categoria
Healthcare
Número de ações em circulação para Amgen Inc. (AMGN)
Número de ações em circulação em June 2026: 540.00M
De acordo com os últimos relatórios financeiros e o preço das ações da Amgen Inc., o número atual de ações em circulação é 540.00M. No final de December 2024, a empresa tinha 541.00M ações em circulação. O número de ações em circulação é geralmente afetado por desdobramentos de ações e recompra de ações.
Histórico de ações em circulação da Amgen Inc. (AMGN) de 2000 a 2026
Ações em circulação no final de cada ano
| Ano | Ações em circulação | Alterar |
|---|---|---|
| 2026 (TTM) | 540.00M | 0.37% |
| 2025 | 538.00M | -0.55% |
| 2024 | 541.00M | 1.12% |
| 2023 | 535.00M | -0.56% |
| 2022 | 538.00M | -5.61% |
| 2021 | 570.00M | -2.73% |
| 2020 | 586.00M | -3.14% |
| 2019 | 605.00M | -8.47% |
| 2018 | 661.00M | -9.58% |
| 2017 | 731.00M | -2.27% |
| 2016 | 748.00M | -1.32% |
| 2015 | 758.00M | -0.13% |
| 2014 | 759.00M | 0.80% |
| 2013 | 753.00M | -2.84% |
| 2012 | 775.00M | -14.36% |
| 2011 | 905.00M | -5.73% |
| 2010 | 960.00M | -5.51% |
| 2009 | 1.02B | -5.05% |
| 2008 | 1.07B | -4.21% |
| 2007 | 1.12B | -5.02% |
| 2006 | 1.18B | -4.85% |
| 2005 | 1.24B | -2.75% |
| 2004 | 1.27B | -1.32% |
| 2003 | 1.29B | 11.66% |
| 2002 | 1.15B | 10.33% |
| 2001 | 1.05B | 1.54% |
| 2000 | 1.03B | 0.00% |
Ações em circulação de empresas semelhantes ou concorrentes
| Empresa | Ações em circulação | Diferença | País |
|---|---|---|---|
| 892.40M | 65.26% |
US
|
|
| 2.45B | 353.25% |
US
|
|
| 1.77B | 227.96% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 47.41% |
CH
|
